All Stories

  1. Comprehensive analysis of clinical data for COVID-19 outcome estimation with machine learning models
  2. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia
  3. Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection
  4. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease
  5. Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
  6. Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
  7. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation
  8. Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
  9. COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation
  10. One Year of the COVID-19 Pandemic in Galicia: A Global View of Age-Group Statistics during Three Waves
  11. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
  12. Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective
  13. Phenotypic characterisation of early COPD: a prospective case–control study
  14. Documento de consenso sobre el diagnóstico y tratamiento de la infección bronquial crónica en la enfermedad pulmonar obstructiva crónica
  15. Current events and action plans in the advancement of thoracic surgery and pulmonology in Spain
  16. Impact of a Home Telehealth Program After a Hospitalized COPD Exacerbation: A Propensity Score Analysis
  17. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
  18. Next-generation sequencing diagnosis of severe pneumonia from fulminant psittacosis with multiple organ failure: a case report and literature review
  19. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia
  20. Clasificación de la hipertensión arterial pulmonar basada en el estudio genético y familiar
  21. Factores que condicionan la pérdida de control al reducir escalones terapéuticos en el tratamiento del asma moderada-grave en la práctica clínica habitual: estudio español multicéntrico
  22. Classification of Pulmonary Arterial Hypertension by Genetic and Familial Testing
  23. EARLY COPD: determinantes de la aparición y progresión de la enfermedad pulmonar obstructiva crónica en adultos jóvenes. Protocolo de un estudio caso-control con seguimiento
  24. Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case–Control Study With Follow-Up
  25. Influenza A H1N1 Community-Acquired Pneumonia: Characteristics and Risk Factors—A Case-Control Study
  26. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease
  27. An international perspective on hospitalized patients with viral community-acquired pneumonia
  28. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
  29. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  30. Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)? CON
  31. Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study
  32. Tratamiento con esteroides sistémicos en agudización grave de enfermedad pulmonar obstructiva crónica: empleo de pautas cortas en práctica clínica habitual y relación con la estancia hospitalaria
  33. High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis
  34. Discordance of physician clinical judgment vs. pneumonia severity index (PSI) score to admit patients with low risk community-acquired pneumonia: a prospective multicenter study
  35. Neumonía subaguda como manifestación de una neumonía organizada fibrosante aguda
  36. Relationship Between Severity Classification of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Clinical Outcomes in Hospitalized Patients
  37. Risk Factors of Poor Outcomes after Admission for a COPD Exacerbation: Multivariate Logistic Predictive Models
  38. Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis
  39. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study
  40. Surgical Lung Biopsy: The Role of Better Surgery
  41. Active strategy in primary care for diagnosing COPD
  42. Reversible Schamroth Sign
  43. Signo de Schamroth reversible
  44. Long-Term Noninvasive Ventilation Among Chronic Respiratory Failure Diseases (Cystic Fibrosis and Other Diseases) Awaiting Lung Transplantation: Key Determinants and Practical Implications
  45. Validación de la versión en español del cuestionario COPD-Q/EPOC-Q de conocimiento de la EPOC
  46. Validation of the Spanish Version of the COPD-Q Questionnaire on COPD Knowledge
  47. Community-Acquired Pneumonia Requiring Hospitalization
  48. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations
  49. Lung cancer in patients living with HIV infection
  50. Organized Pneumonia Secondary to Increasing Doses of Temozolomide
  51. Actualización de GesEPOC 2014 y corticoides sistémicos en la agudización de enfermedad pulmonar obstructiva crónica (EPOC)
  52. 2014 GesEPOC and Systemic Steroids in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation: An Update
  53. Empyema due to Aggregatibacter aphrophilus and Parvimonas micra Coinfection
  54. Empiema secundario a coinfección por Aggregatibacter aphrophilus y Parvimonas micra
  55. Chromogranin A levels and mortality in patients with severe sepsis
  56. Documento de consenso «Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica»
  57. «Ojo» a los broncodilatadores en nebulización
  58. Beware of Nebulized Bronchodilators
  59. Using Standardized Care Bundles in the Emergency Department to Decrease Mortality in Patients Presenting with Community-Acquired Pneumonia (CAP) and Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
  60. Multicentric study on the beta-blocker use and relation with exacerbations in COPD
  61. Enfermedad pulmonar intersticial difusa como primera manifestación de macroglobulinemia de Waldenström: descripción de un caso y revisión de la literatura
  62. Diffuse Interstitial Lung Disease as a First Manifestation of Waldenström's Macroglobulinemia: Case Report and Review of the Literature
  63. Are Pseudomonas aeruginosa Risk Factors Associated With Pseudomonas Acute Exacerbation of COPD?
  64. Validation of the European Respiratory Society Guidelines for Pseudomonas aeruginosa Risk Factors in Patients With COPD Exacerbations
  65. Sternal Mass Presenting as a First Manifestation of Lung Cancer
  66. Lung cancer in HIV-infected patients
  67. Community-Acquired Pneumonia Team Decreases Length of Stay in Hospitalized, Low-Risk Patients With Pneumonia
  68. Lipoma endobronquial
  69. Sternal Mass Presenting as a First Manifestation of Lung Cancer
  70. Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia
  71. Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study
  72. Community acquired pneumonia: severity scores as an adjunct to clinical judgement
  73. De la exclusión a la certidumbre. El recorrido hacia el diagnóstico de la fibrosis pulmonar idiopática
  74. Long-term Follow-up in Patients Diagnosed and Treated for Pulmonary Tuberculosis: What Really Happened With the Lung Function?
  75. Protocolo diagnóstico del tromboembolismo pulmonar
  76. Enfermedad tromboembólica venosa y tromboembolismo pulmonar
  77. Editorial from Guest Editor [Hot topic: Community-Acquired Pneumonia: A Review of Uncommon Topics (Guest Editor: Pedro J. Marcos)]
  78. Macrolides in Community-Acquired Pneumonia: The Importance of the Non-Antimicrobial Effect
  79. Expected Good Prognosis Community Acquired Pneumonia(CAP):the Importance Of A Specialized Care In Order To Avoid Admissions.A Comparative Study
  80. Microepidemias de tuberculosis en 5 brotes escolares: importancia de la tipificación genética de las cepas en su evaluación e interpretación
  81. Síndrome de Lady Windermere
  82. Hemorragia pulmonar y síndrome antifosfolípido primario: aportación de un caso y revisión de la literatura
  83. Lady Windermere Syndrome
  84. The Importance of Genotyping of Strains for the Evaluation and Interpretation of 5 School-Based Epidemic Outbreaks of Tuberculosis
  85. Angiolipomatosis renal y linfangioleiomiomatosis, su relación con la enfermedad de Bourneville